Addition of clinical measures improves risk-prediction models of 30 day post-TJR readmission  by Franklin, P. et al.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A56increased in severity and 13% decreased in severity over 10 years (Fig-1).
Offspring showed a signiﬁcantly higher increase in the mean score
compared to the controls at the medial tibial and femoral sites in par-
ticipants with a cartilage defect at baseline (Fig-2A). Offspring also
showed a signiﬁcantly higher number of incident cartilage defects at
the medial femoral site only in the participants without a defect at
baseline (Fig-2B).
Presence of tibiofemoral cartilage defects was independently associated
with higher odds of presence of effusion (Odd ratio (95%CI) ¼ 2.19 (1.07,
4.47)) at baseline. Presence and severity of JSN, osteophytes and BMLs
predicted change in total knee cartilage defects in unadjusted analysis,
however these associations only persisted for presence (b ¼ þ0.83
(þ0.32, þ1.60)) and severity (b (per grade) ¼ þ0.86 (þ0.02, þ1.70)) of
JSN and severity of BMLs (b (per unit area) ¼ þ0.64 (þ0.10, þ1.20)).
Change in total knee cartilage defects was associated with change in
BMI, pain and BMLs in the unadjusted analysis but these associations
persisted only for BMI (b ¼ þ0.13 (þ0.03, þ0.25)) in the fully adjusted
model. Change in cartilage defects also independently correlated with
change in JSN (r ¼ 0.16, p ¼ 0.04) but not osteophytes. Furthermore,
change in total knee cartilage defects was independently associated
with absolute (b¼ -123.87 (-193.24, -54.50)) and percentage per annum
(b ¼ -0.08 (-0.11, -0.04)) cartilage volume loss (using mixed model
analysis).
Conclusions: Data from this midlife cohort suggests that cartilage
defects are on the OA causal pathway both for symptoms and structure.
Unlike meniscal pathology, cartilage defects have the capacity to heal
over time thus may be amenable to intervention.
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Purpose: Total joint replacement surgery (TJR) is themost common and
costly procedure in the Medicare budget and TJR use is rapidly
expanding among adults under 65 years of age making TJR outcomes an
important public health issue. In September of 2012, the Center for
Medicare and Medicaid Services (CMS) issued preliminary hospital-
speciﬁc reports of ‘risk-adjusted’ 30 day readmission rates after TJR and
in 2013, CMS publicly reported hospital-speciﬁc TJR readmission rates.
The release of publicly reported TJR outcomes illustrates the importance
of accurate comparisons of post-TJR outcomes across hospitals and
surgeons. However, the CMS risk-adjustment models only apply to
patients over 65 years of age, are based solely on administrative billing
data and ICD-9 co-morbidity codes, and lack clinically reﬁnedmeasures.
We evaluated whether the addition of key pre-operative clinical risk
factors would improve the 30 day post-TJR readmission risk-adjustment
model.
Methods:Wemerged CMS patient-level data for those over 65 years of
age enrolled in the ﬁrst 18 months (June 2011-November 2012) in a
national cohort study (FORCE-TJR) of primary TKR and THR patients
from more than 130 surgeons in 22 states. CMS data include date and
ICD-9 codes for co-existing medical conditions up to 12 months pre-TJR
and readmissions within 30 days after TJR to an acute care hospital.
Additional clinical data from the FORCE-TJR cohort include BMI, medical
and musculoskeletal comorbidities, and pre-op patient-reported pain
and function (HOOS/KOOS; SF36).
Results: Five percent of 2560 patients across 31 sites were readmitted.
Readmission rates were greater among men and patients with the fol-
lowing administrative risk factors: older age, history of infection, COPD,
diabetes, disorders of ﬂuid/electrolytes, rheumatoid arthritis, and renal,
hematologic, and vascular conditions (all p>0.01). In addition, read-
mitted patients had lower pre-TJR function scores, a greater number of
knee/hip joints with moderate-to-severe pain, and greater Charlson
index (all p<0.01). In logistic multivariable models, the CMSmodel with
the addition of clinical measures (number of painful joints and Charl-
son) outperformed the CMS core model based only on ICD codes
[C¼0.65 (ICD/CMS) vs 0.76 (ICD þ Clinical model)].
Conclusions: The addition of patient-reported function and the clinical
severity of musculoskeletal and medical conditions co-existing at time
of surgery improved the 30 day readmission prediction model for TJR.
Public reporting based on risk models that do not address the completecomorbid proﬁle, including musculoskeletal conditions, may dis-
advantage hospitals and surgeons treating patients with the most
advanced disease. Further research should validate the enhanced risk
models in both older (Medicare) and younger TJR patients.
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Purpose: Dysregulated chondrocyte activation and differentiation in
articular cartilage is an important mechanism in Osteoarthritis (OA)
pathogenesis. Twist-related protein1 (TWIST1) is known as class A basic
helix-loop-helix protein 38 (bHLHa38), and involved in the negative
regulation of cellular determination and in the differentiation of several
lineages including myogenesis and osteogenesis. TWIST1 is also known
as a factor contributing to dedifferentiation and chondrogenesis. We
also found out TWIST1 was upregulated in human OA knee cartilage
tissue compared with normal knee through next-generation sequenc-
ing. In this study we revealed correlative relationship between TWIST1
and chondrogenesis-related genes (collagen type II alpha (COL2A1),
Sox 9).
Methods: Cartilage tissues and chondrocytes were obtained at autopsy
from normal knee joints (n¼7) and from OA joints (n¼8) at knee
arthroplasty. The expression level of TWIST1 in cartilage tissues were
determined by qRT-PCR. TWIST1 protein expression in cartilage tissue
was analyzed by immunohistochemistry in human and mouse OA
model. Human normal cartilage derived chondrocytes, TC28 (immor-
talized human chondrocytes) and SW1353 (human chondrosarcoma)
cells were used to study regulation of chondrogenesis-related genes by
TWIST1. TWIST1 was knocked down with small interfering RNA
(siRNA), and over expressed by pCMV6-Entry C-terminal Myc tagged
TWIST1 ORF vector. To further investigate the linkage between TWIST1,
COL2A1 and SOX9, we constructed luciferase reporters containing SOX9
3’ UTR, COL2A1 promoter and COL2A1 enhancer segments.
Results: TWIST1 expression was signiﬁcantly increased in human OA
knee cartilages compared to normal knee cartilages (5-6-fold up-reg-
ulation). Immunohistochemistry analysis showed only few Twist pos-
itive cells in normal human andmouse cartilage and increased numbers
of Twist1 positive cells in OA-affected tissues. Following TWIST1 siRNA
treatment of chondrocytes, qRT-PCR results showed SOX9, COL2A1 and
aggrecan gene expressions were up-regulated, and cartilage-degrading
enzymes (MMP-13, ADAMTS4) were down-regulated. In contrast, over
expression of TWIST1 suppressed COL2A1 gene expression, but not
SOX9. Luciferase activities of SOX9 3’UTR and COL2A1 promoter-luci-
ferase reporter were reduced after TWIST1 transfection. TWIST1 also
reduced COL2A1 enhancer-luciferase reporter activity, but there is no
TWIST1 binding site in COL2A1 enhancer. This data shows that TWIST1
might affect COL2A1 enhancer indirectly through SOX9 down-
regulation.
Conclusions: Overexpression of TWIST1 is a novel feature of OA
affected cartilage, and promotes catabolic reaction and abnormal
chondrocyte differentiation by interacting with COL2A1 promoter and
SOX9 3’UTR. Thus, dysregulated TWIST1 may be an important factor in
OA pathogenesis and a novel treatment target for OA.
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Purpose: Osteoarthritis (OA) is the most common degenerative joint
disease and knee OA often requires joint replacement to reduce pain
and restore joint mobility. The role of bone morphogenetic proteins
(BMP) in the pathogenesis of OA remains controversial despite many
years of study. BMP signaling is required for synovial joint formation
during development and is also involved in maintaining the normal
function of synovial joints after birth. Paradoxically, too much BMP
activity is also associated with synovial thickening and osteophyte
formation, hallmarks of OA progression. Mice lacking BMP2 in all limb
bud skeletal progenitors (BMP2-Prx1) develop OA of the elbows and
